128 related articles for article (PubMed ID: 19405786)
21. [Role of pharmacogenetics in chemotherapy of colorectal cancers].
Ceppa F; Fontan E; Cremades S; Bihannic R; Bousquet A; Beauvillain L; Burnat P
Rev Med Interne; 2007 Sep; 28(9):594-602. PubMed ID: 17624636
[TBL] [Abstract][Full Text] [Related]
22. Tailored chemotherapy for colorectal cancer: a new approach to therapy.
Iqbal S; Stoehlmacher J; Lenz HJ
Cancer Invest; 2004; 22(5):762-73. PubMed ID: 15581057
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of stomach cancer.
Toffoli G; Cecchin E
Suppl Tumori; 2003; 2(5):S19-22. PubMed ID: 12914384
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
26. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase pharmacogenetics in colorectal cancer.
Marsh S; McLeod HL
Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
[TBL] [Abstract][Full Text] [Related]
28. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics and stomach cancer: an update.
Toffoli G; Cecchin E
Pharmacogenomics; 2007 May; 8(5):497-505. PubMed ID: 17465714
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
31. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
O'Dwyer PJ; Catalano RB
J Clin Oncol; 2006 Oct; 24(28):4534-8. PubMed ID: 17008691
[No Abstract] [Full Text] [Related]
32. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.
Di Francia R; Siesto RS; Valente D; Spart D; Berretta M
Eur Rev Med Pharmacol Sci; 2012 Sep; 16(9):1211-7. PubMed ID: 23047504
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer.
Kiyohara C
J Epidemiol; 2000 Sep; 10(5):349-60. PubMed ID: 11059519
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of colorectal cancer.
Marsh S
Expert Opin Pharmacother; 2005 Dec; 6(15):2607-16. PubMed ID: 16316300
[TBL] [Abstract][Full Text] [Related]
37. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
Galvani E; Toffalorio F; Peters GJ; De Pas T; Giovannetti E
Curr Pharm Des; 2014; 20(24):3863-74. PubMed ID: 24138720
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]